Efficacy and safety of oral Pcsk9 inhibitors: insights from a meta-analysis of randomized controlled trials (RCTs)
Pooled result · LDL-CResult — go to the resultPooled mean percentage change −59.31 % 95% CI −62.33 to −56.28Authors' conclusion
Oral PCSK9 inhibitors demonstrate potent LDL-C-lowering efficacy, comparable to parenteral PCSK9i, with favourable effects on other atherogenic lipids and a reassuring short-term safety profile.
Study context
- Population
- Hypercholesterolemia on stable background lipid-lowering therapy
- Participants
- 3,295 participants5 RCTs
- Comparison
- Oral PCSK9 inhibitors vs placebo
- Outcome
- LDL-C change (pooled mean percentage change)
- Follow-up
- 8 to 24 weeks
Methodological detailsrandom- and fixed-effects models
- Random- and fixed-effects models
Pooled result
LDL-C
Pooled mean percentage change
−59.31 %
95% CI −62.33 to −56.28
Oral PCSK9 inhibitors vs Placebo
pooled mean percentage change −59.31 % (95% CI −62.33 to −56.28)
As reported in the abstract
Further pooled results
Apolipoprotein B
- Pooled mean % change in apolipoprotein B
- −49.53% (95% CI −54.19 to −44.79)
Non-HDL cholesterol
- Pooled mean % change in non-HDL cholesterol
- −55.41% (95% CI −57.35 to −53.48)
Lipoprotein(a)
- Pooled mean % change in Lipoprotein(a)
- −22.74% (95% CI −26.67 to −18.81)
Safety
| Outcome | RR (95% CI) | P value | |
|---|---|---|---|
| Serious adverse eventsNo increased risk | 0.84 (0.68–1.03) | P = 0.41 | |
| 0.512Relative risk (log scale) |
Original publication
Efficacy and safety of oral Pcsk9 inhibitors: insights from a meta-analysis of RCTs. Eur J Prev Cardiol. Published 22 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →